Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA First-Generic Notification Policy May Be Reviewed

Executive Summary

FDA will re-examine whether it is legally barred from notifying a generic company early in the ANDA process that it is the first filer eligible for 180-day exclusivity, Chief Counsel Dan Troy said Sept. 30

You may also be interested in...



Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes

U.S. FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.

Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes

FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.

U.S. Generic Exclusivity Process To Go Public?

The U.S. FDA wants to know whether its 180-day generic exclusivity process should be revealed up front; the question will be one of many on ANDA reviews to be considered at a September public hearing.

Related Content

UsernamePublicRestriction

Register

PS042566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel